+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07574047

Chronotherapy Study Evaluating Morning Versus Afternoon Immune Checkpoint Inhibitor Infusions for Advanced Melanoma Patients A Phase II Randomized Trial

Led by Swiss Cancer Institute · Updated on 2026-10-27

108

Participants Needed

9

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how the timing of immune checkpoint inhibitor ICI therapy affects treatment outcomes in people with advanced melanoma. The study focuses on whether giving these therapies earlier in the day, aligned with the bodys natural immune rhythms, can improve effectiveness, especially in female patients. This prospective, randomized trial aims to clarify the complex relationship between sex, circadian immune function, and response to ICIs. Participants will be randomly assigned to receive standard-of-care ICI treatments during either an early morning window 800 to 1200 or a late afternoon window 1500 to 1800. The treatments include drugs such as nivolumab, pembrolizumab, and the combination of ipilimumab with nivolumab, given intravenously on schedules typical for each medication. Treatment phases include induction and maintenance cycles depending on the therapy used, with dosing intervals ranging from every 2 to 4 weeks. During the study, participants will be monitored from the time of randomization up to six years to assess progression-free survival, overall survival, and objective response rate. Researchers will conduct regular clinical assessments and follow participants closely to evaluate treatment effects and safety. The trial emphasizes personalized timing of treatment to potentially enhance immune response without additional costs or toxicity.

CONDITIONS

Brief Title

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

Research Team

L

Lenka Vokalova, PhD

C

Christina Müller, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here